These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18220788)

  • 1. Modeling and informatics in designing anti-diabetic agents.
    Bharatam PV; Patel DS; Adane L; Mittal A; Sundriyal S
    Curr Pharm Des; 2007; 13(34):3518-30. PubMed ID: 18220788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG; Somsák L
    Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
    Musoev A; Numonov S; You Z; Gao H
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current anti-diabetic agents and their molecular targets: A review.
    Kerru N; Singh-Pillay A; Awolade P; Singh P
    Eur J Med Chem; 2018 May; 152():436-488. PubMed ID: 29751237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors.
    Bibi S; Sakata K
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):319-335. PubMed ID: 28382867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
    Habash M; Taha MO
    Bioorg Med Chem; 2011 Aug; 19(16):4746-71. PubMed ID: 21788139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Docking, In-Silico ADMET Study and Development of 1,6- Dihydropyrimidine Derivative as Protein Tyrosine Phosphatase Inhibitor: An Approach to Design and Develop Antidiabetic Agents.
    Patel AD; Barot R; Parmar I; Panchal I; Shah U; Patel M; Mishtry B
    Curr Comput Aided Drug Des; 2018; 14(4):349-362. PubMed ID: 29701158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling and statistical analysis in the design of derivatives of human dipeptidyl peptidase IV.
    Pereira ALE; Dos Santos GB; Franco MSF; Federico LB; da Silva CHTP; Santos CBR
    J Biomol Struct Dyn; 2018 Feb; 36(2):318-334. PubMed ID: 28027711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR studies in the discovery of novel type-II diabetic therapies.
    Abuhammad A; Taha MO
    Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H; Wang YT; Tsai JJ; Chen YC
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents.
    Saqib U; Siddiqi MI
    SAR QSAR Environ Res; 2009 Jul; 20(5-6):519-35. PubMed ID: 19916112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computation as a tool for glycogen phosphorylase inhibitor design.
    Hayes JM; Leonidas DD
    Mini Rev Med Chem; 2010 Oct; 10(12):1156-74. PubMed ID: 20716053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of synthetic drugs for type 2 diabetes drug discovery.
    Safavi M; Foroumadi A; Abdollahi M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1339-63. PubMed ID: 24050217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative structure-activity relationship (QSAR) and design of novel ligands that demonstrate high potency and target selectivity as protein tyrosine phosphatase 1B (PTP 1B) inhibitors as an effective strategy used to model anti-diabetic agents.
    Arthur DE; Ejeh S; Uzairu A
    J Recept Signal Transduct Res; 2020 Dec; 40(6):501-520. PubMed ID: 32397858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
    Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H
    Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
    Al-Masri IM; Mohammad MK; Taha MO
    ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment.
    Pissurlenkar RR; Shaikh MS; Coutinho EC
    J Mol Model; 2007 Oct; 13(10):1047-71. PubMed ID: 17676345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTP1b Inhibition, A Promising Approach for the Treatment of Diabetes Type II.
    Eleftheriou P; Geronikaki A; Petrou A
    Curr Top Med Chem; 2019; 19(4):246-263. PubMed ID: 30714526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.